Abstract
Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 1800-1814 |
Number of pages | 15 |
Journal | Viruses |
Volume | 3 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2011 |
Keywords
- DNA vaccine
- Dengue vaccine
- Sub-unit protein vaccine
- Vectored-vaccine
ASJC Scopus subject areas
- Infectious Diseases
- Virology